Drug
Crenezumab clinical trials
Also written MABT5102A and RO5490245.
How studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses crenezumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier CohortCompletedPhase 2Genentech, Inc.NCT01998841Written as Crenezumab
- Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseCompletedPhase 2Hoffmann-La RocheNCT03977584Written as Crenezumab
- A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT03114657Written as Crenezumab
- A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).TerminatedPhase 3Hoffmann-La RocheNCT02670083Written as Crenezumab
- An Open-Label Crenezumab Study in Participants With Alzheimer's DiseaseTerminatedPhase 3Hoffmann-La RocheNCT03491150Written as Crenezumab
- A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With CrenezumabCompletedPhase 2Genentech, Inc.NCT01723826Written as Crenezumab
- A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)CompletedPhase 2Genentech, Inc.NCT01343966Written as MABT5102A
- A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2Genentech, Inc.NCT01397578Written as MABT5102A
- A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT00997919Written as MABT5102A
- A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous DoseCompletedPhase 1Genentech, Inc.NCT02427243Written as Crenezumab
Codes
What other systems call crenezumab · ClinicalTrials.gg INT006092
- MeSH (NLM) C573372crenezumabOne source NLM
- UNII (FDA) O8AS5277H0CRENEZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5184156crenezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174789CrenezumabOne source FDA
- DrugBank DB11959One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C573372 | crenezumab | One source NLM |
| UNII (FDA) | O8AS5277H0 | CRENEZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5184156 | crenezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174789 | Crenezumab | One source FDA |
| DrugBank | DB11959 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.